Decongestants, antihistamines and nasal irrigation for acute sinusitis in children

General Academic Pediatrics, Children's Hospital of Pittsburgh, 3414 Fifth Ave, Suite 301, Pittsburgh, PA, USA, 15213.
Cochrane database of systematic reviews (Online) (Impact Factor: 5.94). 01/2010; DOI: 10.1002/14651858.CD007909.pub2
Source: PubMed

ABSTRACT The efficacy of decongestants, antihistamines and nasal irrigation in children with clinically diagnosed acute sinusitis has not been systematically evaluated.
To systematically review the efficacy of decongestants, antihistamines and nasal irrigation in children with clinically diagnosed acute sinusitis. We considered the following four interventions: 1) decongestants versus placebo or no medication, 2) antihistamines versus placebo or no medication, 3) decongestant and antihistamine combination versus placebo or no medication, 4) nasal irrigation versus no irrigation. The primary outcomes of the review were symptom resolution (improvement in symptom score from enrolment to day 5) and overall symptom burden (as measured by average symptom scores while on therapy).
We searched the Cochrane Register of Controlled Trials (CENTRAL) (The Cochrane Library Issue 2, 2010), which includes the Acute Respiratory Infections Group's Specialized Register, MEDLINE (1950 to May Week 1, 2010) and EMBASE (1950 to January 2010).
We included randomized controlled trials (RCTs) and quasi-RCTs which evaluated children less than 18 years of age with acute sinusitis, defined as 10 to 30 days of rhinorrhea, congestion or daytime cough. We excluded trials of children with chronic sinusitis and allergic rhinitis.
Two review authors independently assessed each study for inclusion.
Of the 402 studies found through the electronic searches and handsearching, none met all the inclusion criteria.
There is no evidence to determine whether the use of antihistamines, decongestants or nasal irrigation is efficacious in children with acute sinusitis. Further research is needed to determine whether these interventions are beneficial in the treatment of children with acute sinusitis.

  • [Show abstract] [Hide abstract]
    ABSTRACT: La pathologie ORL est fréquente en soins primaires, chez l’adulte et l’enfant, et s’accompagne souvent de douleur. Les douleurs à point de départ ORL sont souvent liées à des infections virales, voire bactériennes, affectent l’oreille elle-même ou sont projetées, et font craindre alors une pathologie carcinologique. L’infirmière qui accueille le patient peut par l’interrogatoire identifier la douleur: son intensité (importante au stade aigu), la chronologie (aiguë paroxystique, chronique), les signes associés (rhinologiques, toux, fièvre, troubles du sommeil) mais également le contexte: l’anxiété vis-à-vis d’une pathologie grave (cancer, céphalée vasculaire…). Elle participe à l’information du patient, réassure l’entourage et les parents quand il s’agit d’enfants. Les pathologies les plus fréquemment rencontrées sont les affections rhinosinusiennes, pharyngolaryngées, l’otite moyenne de l’enfant ainsi que la pathologie cancéreuse ORL.
    Douleur et Analgésie 09/2012; 25(3). DOI:10.1007/s11724-012-0302-z · 0.09 Impact Factor
  • Source
    01/2011; Ministry of Health, Damascus.
  • [Show abstract] [Hide abstract]
    ABSTRACT: In this review we celebrate a century of progress since the initial description of the physiologic and pathologic roles of histamine and 70 years of progress since the introduction of H(1)-antihistamines for clinical use. We discuss histamine and clinically relevant information about the molecular mechanisms of action of H(1)-antihistamines as inverse agonists (not antagonists or blockers) with immunoregulatory effects. Unlike first (old)-generation H(1)-antihistamines introduced from 1942 to the mid-1980s, most of the second (new)-generation H(1)-antihistamines introduced subsequently have been investigated extensively with regard to clinical pharmacology, efficacy, and safety; moreover, they are relatively free from adverse effects and not causally linked with fatalities after overdose. Important advances include improved nasal and ophthalmic H(1)-antihistamines with rapid onset of action (in minutes) for allergic rhinitis and allergic conjunctivitis treatment, respectively, and effective and safe use of high (up to 4-fold) doses of oral second-generation H(1)-antihistamines for chronic urticaria treatment. New H(1)-antihistamines introduced for clinical use include oral formulations (bilastine and rupatadine), and ophthalmic formulations (alcaftadine and bepotastine). Clinical studies of H(3)-antihistamines with enhanced decongestant effects have been conducted in patients with allergic rhinitis. Additional novel compounds being studied include H(4)-antihistamines with anti-inflammatory effects in allergic rhinitis, atopic dermatitis, and other diseases. Antihistamines have a storied past and a promising future.
    The Journal of allergy and clinical immunology 12/2011; 128(6):1139-1150.e4. DOI:10.1016/j.jaci.2011.09.005 · 11.25 Impact Factor


Available from